logo
Plus   Neg
Share
Email

Ford Vehicles Probed For Stalling On Highway

The National Highway Traffic Safety Administration (NHTSA) is investigating problems with stalling and/or surging engines in nearly 775,000 Ford passenger cars and SUVs. The government agency and Ford have received 1,500 complaints about the issue. One injury has been reported.

The vehicles affected by the investigation are the 2009 through 2011 models of Ford Escape and Mercury Mariner SUVs and Ford Fusion and Mercury Milan sedans.

According to the NHTSA, the engines do not quit but shift into one of three reduced-power "limp-home" modes. The sudden cut in power can feel to a driver as if the engine stalled.

"Depending on the condition of throttle control system malfunction, a driver may experience varying levels of reduced engine performance associated with three limp home modes. In two limp modes, reduced engine performance may maintain vehicle speeds above 20mph while the third is a limited limp home mode with engine speeds limited to approximately 900 RPM," said NHTSA.

No recall has been issued yet.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT